We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology

News   Aug 19, 2011

 
Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology
 
 
Advertisement
 

RELATED ARTICLES

Portable 90-Minute COVID-19 Test CovidNudge Matches Labs for Accuracy

News

Since the emergence of the novel coronavirus SARS-CoV-2, scientists, physicians and key workers have all been calling for more rapid diagnostic testing. A new study from Imperial College London details a device that can give test results in just 90 minutes.

READ MORE

Study of Over 1 Million People Suggests Blood Type O May Protect Against COVID-19

News

In June, Technology Networks reported on some of the initial findings from personal genomics and biotechnology company 23andMe's COVID-19 genetic study. These results lent further evidence to earlier suggestions that an individual's blood type – determined by a gene known as ABO – may be associated with COVID-19 susceptibility. Now, 23andMe scientists have published results from the first four months of the study which has collected data from over 1 million research participants.

READ MORE

Phase 3 Clinical Trial of Belimumab for Lupus Nephritis Reports Positive Results

News

Results from the largest Phase 3 lupus nephritis clinical trial ever conducted were announced, September 16. The study, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis, a condition that causes inflammation in the kidneys of patients with systemic lupus erythematosus.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE